Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin Add-on to Metformin in T2DM
NCT00086515Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2004
- Primary completion
- Jul 2005
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Sitagliptin 100 mg with Placebo / Glipizide 5 mg (2 arms). Primary endpoint: Change From Baseline in Hemoglobin A1C at 24 weeks. Started Jun 2004; status: completed.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00086515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00086515.